RxDoctor Payments DataLook up a doctor →

Tanis Bast

Family · Union, MONPI 1295193274

Payments from drug & device makers

$38,386in general payments, 2019–2025

Across 531 payments — averaging $72.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$22K
  • Braeburn Inc.$10K
  • AbbVie$1K
  • Indivior Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$538
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$457
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$5601%
  • Speaking & faculty fees$22,82359%
  • Travel & lodging$5,34314%
  • Food & beverage$9,64525%
  • Education$150%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,386 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$4,650
Medicare patients
16
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VivitrolNaltrexone Microspheres106$173,522
SublocadeBuprenorphine26$55,393
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl210$19,336
BrixadiBuprenorphine12$18,904
TrintellixVortioxetine Hydrobromide13$6,933
Naltrexone Hcl37$904
Aripiprazole18$856
Quetiapine Fumarate83$693
Hydroxyzine Hcl21$309
Buspirone Hcl17$161
Fluoxetine Hcl25$128
Bupropion XlBupropion Hcl12$122
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$109
Mirtazapine13$103
Sertraline Hcl43$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Vivitrol$21,539$173,522106 claims
Indivior Inc.Sublocade$1,149$55,39326 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$16$19,336210 claims
Braeburn Inc.Brixadi$9,741$18,90412 claims
Lilly USA, LLCOlanzapine$423$8011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Union

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →